The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-α

Haematologica

Volumn 89, Issue 1, 2004, Pages 42-48

  Roman Gomez, José ^a   Jimenez Velasco, Antonio ^b   Castillejo, Juan A ^a   Cervantes, Francisco ^c   Barrios, Manuel ^b   Colomer, Dolors ^c   Heiniger, Anabel ^b   Torres, Antonio ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

BCR ABL; CML; IFN; SOCS 1

Indexed keywords

ALPHA INTERFERON; CYTARABINE; RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERFERON-ALPHA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PROGNOSIS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0842328525     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-42.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarini M, Cervantes, F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;384:994-1004.
3. Roman-Gomez J, Castillejo JA, Jimenez A, Cervantes F, Boque C, Hermosin L, et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon-alfa. J Clin Oncol 2003;21:1472-9.
4. Darnell JE, Kerr IM, Stark GM. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-20.
5. Fu XY, Schindler C, Improta T, Aebersold R, Darnell JE. The proteins of ISGF-3, the interferon-α-induced transcription activator, define a gene family involved in signal transduction. Proc Natl Acad Sci USA 1992;89:7840-3.
6. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signaling. Nature 1997;387:917-21.
7. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-9.
8. Chen XP, Losman JA, Rothman P. SOCS protein, regulators of intracellular signaling. Immunity 2000;13:287-90.
9. Sakai I, Takeuchi K, Yamauchi H, Fujita S. Constitutive expression of SOCS-3 confers resistance to IFN-α in chronic myelogenous leukemia cells. Blood 2002;100:2926-31.
10. Schultheis B, Carapeti-Mannotian M, Hocchaus A, Weiber A, Goldman JM, Melo JV. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 2002;99:1766-75.
11. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
12. Kantarjian HM, Dixon D, Keating MF, Talpaz M, Walters RS, McCredie KB, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441-6.
13. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 1990;88:1-8.
14. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarini M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon α. J Natl Cancer Inst 1998;90:850-8.
15. Talpaz M, McCredie K, Kantarjian H, Trujillo J, Keating M, Gutterman J. Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br J Haematol 1986;64:87-95.
16. Borrow J, Goddard AD, Gibbons B, Katz F, Swirsky D, Fioretos T, et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol 1992;82:529-40.
17. Gaiger A, Henn T, Horth E, Geissler K, Mittebauer G, Maier-Dobersberger T, et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995;86:2371-8.
18. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, et al. SOCS-1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal actions of this cytokine. Cell 1999;98:597-608.
19. Starr R, Metcalf D, Elefanty AG, Brysha M, Willson TA, Nicola NA, et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 1998;95:14395-9.
20. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 1998;273:35056-62.
21. Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP, et al. Interleukin-10 inhibits expression of both interferon-α and interferon-γ induced genes by suppressing tyrosine phosphorylation of STAT-1. Blood 1999;93:1456-63.
22. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 2001;21:3547-57.
23. Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho J M-Y, Nguyen MH-H, et al. The tumor suppressor activity of SOCS-1. Oncogene 2002;21:4351-62.
24. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, et al. Stat5α/β is essential for the myelo- and lymphoproliferative disease induced by TEL-JAK2. Mol Cell 2000;6:693-704.
25. Sexl VR, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD, et al. Stat5α/β contribute to interleukin-1-induced B-cell precursor expansion, but abl and bcr-abl-induced transformation are independent of Stat5. Blood 2000;96:2277-83.